louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01243853: Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
Official title: Alpha-galactosidase Enzyme and Irritable Bowel Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Irritable Bowel Syndrome
Lead sponsor: Verman Oy Ab
Sponsor class: INDUSTRY
First posted: 2010-11-19
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of IBS according to Rome III criteria, additionally abdominal distension or flatulence the most disturbing symptom
* Age 18-65 years
* Colonoscopy conducted within the previous 5 years, finding macroscopically and histologically normal

Exclusion Criteria:

* Organic GI disease. Treated (min. 1 year) coeliac disease patients, and subjects with known and treated lactose intolerance are allowed to participate
* Malignancy
* Significant gastrointestinal surgery
* Clinically significant aberrancies in the screening-phase laboratory analyses
* Changes in regular medication during the previous 4 weeks
* Pregnancy or breast feeding
* Other disease or state that based on the investigator's evaluation complicates the conduction of the intervention, i.e. alcoholism, dementia
* Hereditary galactosemia

Primary outcomes:
measure: IBS symptom severity
timeFrame: baseline
measure: IBS symptom severity
timeFrame: 1 month
measure: IBS symptom severity
timeFrame: 2 months
measure: IBS symptom severity
timeFrame: 3 months
measure: IBS symptom severity
timeFrame: follow-up (4 months)
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Gastrolääkärit Oy
Study officials:
affiliation: Gastrolääkärit Oy
name: Jari Koskenpato, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01956877: Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers
Official title: Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2013-10-08
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 15 healthy volunteers, age \> years

Brief summary: To assess normal values of EGJ distensibility in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

1. No history of gastrointestinal disease, especially gastro-esophageal reflux disease
2. BMI = 18-30 kg/m²
3. Caucasian race
4. Subject signed the informed consent form and is able to adhere to study protocol

Exclusion Criteria:

1. Age \< 18 years
2. Previous esophageal or gastric surgery
3. Co-morbidities (including cardiopulmonary disease, collagen diseases, obesity, coagulation disorders and co-morbidity hindering upper gastrointestinal endoscopy)
4. Patients using anticoagulants
5. Patients unable to give informed consent
6. Smoking
7. History of alcohol abuse or current excessive alcohol consumption (\> 2 alcoholic beverages per day or \> 14 alcoholic beverages per week)

Primary outcomes:
measure: normal values of esophagogastric junction (EGJ) distensibility (mm2/mmHg) in healthy volunteers as measured with the EndoFLIP device
timeFrame: 3 months
Secondary outcomes:
measure: Establishing a cut-off value of EGJ distensibility (mm2/mmHg) based on the 90% percentile distribution of measurements performed in healthy volunteers.
timeFrame: 3 months
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
Study officials:
References:
Clinical trial NCT03364777: The Correlations Between Clinical Effect and Emotional State
Official title: Analysis of Correlations Between Preoperative Emotional State and Postoperative Clinical Effect in Patients Undergoing Lumbar Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Emotional Disorder
Keywords: lumbar surgery, emotional state
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-12-07
Enrollment: 100
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients undergoing lumbar surgery for lumbar degenerative diseases with or without emotional state of anxiety and depression evaluated by emotional scales.

Brief summary: To analyze the correlations between preoperative emotional state and postoperative clinical effect among patients undergoing lumbar surgery

Detailed description: Preoperative emotional state and postoperative clinical effect of patients undergoing lumbar surgery will be evaluated and compared. Then the relations of anxiety and depression on quality of life will be analyzed.

Eligibility criteria: Inclusion Criteria:

1. patients with relevant symptoms of lumbar degenerative diseases;
2. patients with bad emotional state,such as anxiety or depression.

Exclusion Criteria:

1. spinal tumor;
2. spinal trauma;
3. congenital spinal disease;
4. patients diagnosed psychosis;
5. patients with incomplete clinical informations.

Primary outcomes:
measure: changes of patient's quality of life
timeFrame: Baseline and two weeks postoperative
Secondary outcomes:
measure: changes of patients's emotional state
timeFrame: Baseline and two weeks postoperative
Other outcomes:
Locations:
Study officials:
affiliation: spinal surgery
name: Haiying Liu, doctor
role: STUDY_DIRECTOR
References:
citation: Floyd H, Sanoufa M, Robinson JS. Anxiety's Impact on Length of Stay Following Lumbar Spinal Surgery. Perm J. 2015 Fall;19(4):58-60. doi: 10.7812/TPP/15-022.
citation: Falavigna A, Righesso O, Teles AR, Baseggio N, Velho MC, Ruschel LG, Abruzzi F, Silva PG. Depression Subscale of the Hospital Anxiety and Depression Scale applied preoperatively in spinal surgery. Arq Neuropsiquiatr. 2012 May;70(5):352-6. doi: 10.1590/s0004-282x2012000500009.
citation: D'Angelo C, Mirijello A, Ferrulli A, Leggio L, Berardi A, Icolaro N, Miceli A, D'Angelo V, Gasbarrini G, Addolorato G. Role of trait anxiety in persistent radicular pain after surgery for lumbar disc herniation: a 1-year longitudinal study. Neurosurgery. 2010 Aug;67(2):265-71. doi: 10.1227/01.NEU.0000371971.51755.1C.
Clinical trial NCT05955677: Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Official title: Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis, Recurrence, and Metastasis: a Prospective Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Prostate Cancer
PET/CT
Lead sponsor: Anhui Provincial Hospital
Sponsor class: OTHER_GOV
First posted: 2023-07-21
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[68Ga\]Ga-PSMA-D5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[68Ga\]Ga-PSMA-11.

Detailed description: \[68Ga\]Ga-PSMA-D5 PET/CT was used for initial assessment of prostate cancer or detection of recurrence. The maximum standardized uptake value (SUVmax) was used to evaluate tumor uptake. The sensitivity, specificity, the number and accuracy of lesions identified and the distribution of lesions in each organ were calculated and compared with those of \[68Ga\]Ga-PSMA-11 PET/CT.

Eligibility criteria: Inclusion Criteria:

* Aged from 18 to 90 years old;
* Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
* Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
* simultaneous \[68Ga\]Ga-PSMA-D5 and \[68Ga\]Ga-PSMA-11 examinations within two weeks;
* Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
* Sign informed consent.

Exclusion Criteria:

* Patients who cannot cooperate with the examination;
* Concurrent malignant tumors;
* Previous alcohol allergy;
* Patients with liver and kidney dysfunction;
* Other circumstances deemed by the investigator to be inappropriate for trial participation.

Primary outcomes:
measure: Standard uptake value(SUV)
timeFrame: 30 days
Secondary outcomes:
measure: Diagnostic efficacy
timeFrame: 30 days
measure: Number of lesions
timeFrame: 30 days
Other outcomes:
Locations:
city: Hefei
country: China
facility: The First Affiliated Hospital of China University of Science and Technology（Anhui Provincial Hospital）
state: Anhui
Study officials:
affiliation: The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
name: Qiang Xie
role: STUDY_CHAIR
References:
Clinical trial NCT02064777: Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation
Official title: Tacrolimus Disposition in Pediatric Transplantation: Influence of Age, Genetic Polymorphisms, Intestinal and Hepatic Relative Contribution on Pharmacokinetics, in Relationship With Clinical Outcomes
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pediatric Liver Transplantation
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2014-02-17
Enrollment: 60
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Our first aim is thus to investigate, retrospectively first and then prospectively, in de novo pediatric (living donor) liver recipients, the tacrolimus in vivo and in vitro metabolism and its variability with focus on pharmacokinetics, pharmacodynamics, and pharmacogenomics and its evolution according to the age and transplant delay. Our second aim is then to find better tacrolimus exposure markers for therapeutic drug monitoring (TDM) such as Area Under the time-concentration Curve (AUC) or intralymphocytic (PBMCs) tacrolimus concentration and a way to model and predict it without invasive tests in pediatric patients.

The final objective should be then to implement these findings in a more individualized and comprehensive immunosuppression protocol and monitoring in order to maintain adequate and well-balanced immunosuppression (preventing graft rejection while avoiding acute and long-term side effects). This is particularly important for a pediatric population exposed throughout their life to immunosuppressants.


Eligibility criteria: Inclusion Criteria:

* Children aged 0 to 18 years
* First Liver transplantation
* Children eligible to receive tacrolimus post transplantation
* Consent from parents

Exclusion Criteria:

* Multiorgan transplantation
* Retransplantation
* ABO incompatible donors (unless if recipients is\<1 year and anti-AB antibodies are \<1/32)
* Multi organ failure
* Need for additionnal therapy except for methylprednisolone to treat rejection
* Intravenous tacrolimus
* First tacrolimus administration postponed after day 3

Primary outcomes:
measure: Area Under the Time Concentration curve
timeFrame: day 2-day 4; day 10-day 1; > day 21
Secondary outcomes:
measure: Intralymphocytic tacrolimus concentration
timeFrame: Day 3
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques Universitaires St-Luc
Study officials:
References:
Clinical trial NCT04014777: Study of NGM621 in Participants With Geographic Atrophy
Official title: A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Geographic Atrophy
Lead sponsor: NGM Biopharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2019-07-10
Enrollment: 15
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a multi-center evaluation of NGM621 in an open-label, single-dose and multiple-dose escalation study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.


Eligibility criteria: Inclusion Criteria:

1. GA lesion size in the study eye of \>=2.5 mm² as assessed by the central reading center
2. BCVA - 54 to 4 letters (20/80 to 20/400 Snellen equivalent) using the standard ETDRS (Early Treatment of Diabetic Retinopathy Study) in the study eye at the Screening and Baseline visits; the fellow eye must have a BCVA of at least 69 letters (Snellen equivalent 20/40) at the Screening and Baseline visits

Exclusion Criteria:

1. GA in either eye because of cause other than AMD
2. History or evidence of glaucoma or ocular hypertension in either eye as defined by investigator
3. Visual impairment in the study eye due to causes other than GA
4. Spherical equivalent of the refractive error in the study eye demonstrating more than -6 Diopters of myopia (prior to cataract or refractive surgery)

Other protocol-defined inclusion/exclusion criteria could apply.

Primary outcomes:
measure: Incidence and Severity of Ocular and Systemic Treatment-Emergent Adverse Events (TEAEs)
timeFrame: 12 weeks
Secondary outcomes:
measure: Serum Concentration of NGM621
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Arcadia
country: United States
facility: NGM Clinical Study Site
state: California
city: Newport Beach
country: United States
facility: NGM Clinical Study Site
state: California
city: Melbourne
country: United States
facility: NGM Clinical Study Site
state: Florida
city: Saint Petersburg
country: United States
facility: NGM Clinical Study Site
state: Florida
city: Austin
country: United States
facility: NGM Clinical Study Site
state: Texas
city: The Woodlands
country: United States
facility: NGM Clinical Study Site
state: Texas
Study officials:
affiliation: NGM Biopharmaceuticals
name: NGM Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00829777: Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects
Official title: A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Opiate Addiction
Keywords: Naloxone
6β-Naltrexol
Opioid-dependent
Pharmacokinetics
peripheral effects of withdrawal
central effects of withdrawal
Lead sponsor: California Pacific Medical Center Research Institute
Sponsor class: OTHER
First posted: 2009-01-27
Enrollment: 8
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects


Eligibility criteria: Inclusion Criteria:

* Opiate dependent males and females age 21-45 on stable doses of methadone
* Fluent English speaker
* Willing and able to give written consent

Exclusion Criteria:

* Pregnancy or lactation

FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.

Primary outcomes:
measure: - 6β-Naltrexol will have 13 hr half-life. Plasma collected
timeFrame: -0-24 hrs post dose
measure: - 6β-Naltrexol pharmacokinetic profile in opioid-dependent population will be similar in non-opioid-dependent population. Plasma levels collected
timeFrame: 0-8 hrs post dose
Secondary outcomes:
measure: -6β-Naltrexol will have a lower potency in precipitating withdrawal and be better tolerated than Naloxone assessed by vital signs, objective/subjective ate Withdrawal Scales, Visual Analog Scales, Pupil Size and GI Motility measures
timeFrame: 0-8 hrs post dose
measure: 6β-Naltrexol dose-dependent increases to reverse methadone-induced bowel dysfunction. Plasma levels and Hydrogen Breath Tests
timeFrame: 0-8 hrs post dose
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: CPMC Addiction & Pharmacology Research Laboratory (APRL)
state: California
Study officials:
affiliation: California Pacific Medical Center Research Institute
name: John E Mendelson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01300377: A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery
Official title: A DOUBLE-BLIND RANDOMIZED TRIAL ASSESSING THE ASSOCIATION BETWEEN TYPE OF LOCAL ANESTHESIA TREATMENT AND POSTOPERATIVE PAIN IN PATIENTS IN HAVING UNDERGONE ARRHYTHMIA SURGERY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-operative Pain
Keywords: Post-operative pain
pain
pacemaker
defibrillator
post-operative narcotic use
local anesthesia
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2011-02-21
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of the proposed study is to investigate the relationship between two standard treatments, lidocaine or a mixture of lidocaine and bupivacaine, and 1) postoperative pain, and; 2) narcotic use following pacemaker or defibrillator insertion in subjects who undergo arrhythmia surgery at Baylor Heart and Vascular Institute while adjusting for pertinent clinical and/or demographic factors. No control group is necessary.

Detailed description: Patients receiving a pacemaker or defibrillator are currently given Bupivacaine, Lidocaine, or a mixture of the two for local anesthetic treatment (in addition to general anesthesia). The choice of local anesthetic to be used during surgery is based primarily on the differences in time for the anesthetic to take effect and duration thereafter. Lidocaine typically works in less than 1 minute and lasts approximately 45 minutes. Bupivacaine works within 2 to 3 minutes and lasts 4 to 6 hours. Lidocaine is often preferable due to its shorter time of effectiveness. However, its relatively short duration may translate into a higher use of narcotics for pain management during postoperative care - particularly within the first hour following emergence from general anesthesia. Therefore it is conceivable that these patients would have higher levels of pain, higher cost of care related to cost of narcotics, and higher cost of caregiver time required to administer them.

Eligibility criteria: Inclusion Criteria:

* Arrythmia patients receiving pacemaker or cardiac defibrillator devices at Baylor Heart and Vascular Institute.

Exclusion Criteria:

* Receiving complicated procedures
* Replacement of parts, not inclusive of leads

Primary outcomes:
measure: Pain Scores on the Visual Analog Scale
timeFrame: 3 Years
Secondary outcomes:
measure: Total Post-Operative Narcotic Use
timeFrame: 3 Years
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor Jack and Jane Heart and Vascular Institute
state: Texas
Study officials:
References:
Clinical trial NCT04421677: Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Official title: Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Inclusion Body Myositis
Sporadic Inclusion Body Myositis
Keywords: Inclusion Body Myositis
IBM
PBA
Phenylbutyrate
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2020-06-09
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot study (phase 1 clinical trial) to evaluate the safety and tolerability of phenylbutyrate in IBM. In this open label study, 10 patients with sporadic inclusion body myositis will be treated with phenylbutyrate (3 gm twice daily) for 3 months. There will be a run-in period, during which certain biomarkers will be measured at baseline and at the end of the run-in period in addition to final measurement at the end of the treatment period.


Eligibility criteria: Inclusion Criteria:

* Fulfill ENMC 2011 diagnostic criteria for IBM
* Age \> 18 years
* Women must be post-menopausal (no menses in \>12 months) or status post hysterectomy
* Able to give informed consent

Exclusion Criteria:

* Presence of any one of the following medical conditions: chronic infection; chronic renal insufficiency; cancer other than skin cancer less than five years prior; multiple sclerosis or prior episode of central nervous system demyelination; or other chronic serious medical illnesses
* Presence of any of the following on routine blood screening: WBC\<3000; Platelets \< 100,000; hematocrit \< 30%; BUN \> 30 mg %; creatine \> 1.5 mg%; liver disease with serum albumin \< 3 G/DL
* Women who are pregnant or lactating
* History of non-compliance with other therapies
* Coexistence of other muscular disease
* Drug or alcohol abuse within past three months
* Known bleeding disorder
* Known liver disease
* Known congestive heart failure
* Known hypernatremia
* Inability to give informed consent

Primary outcomes:
measure: Safety and Tolerability of Phenylbutyrate Measured by Incidence of Adverse Events
timeFrame: Month 3 - Month 6
Secondary outcomes:
measure: Inclusion Body Myositis Functional Rating Scale (IBMFRS)
timeFrame: Month 6
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
affiliation: University of Kansas Medical Center
name: Duaa Jabari, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00433277: Autoimmunity in Retinitis Pigmentosa
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Retinitis Pigmentosa
Lead sponsor: Semmelweis University
Sponsor class: OTHER
First posted: 2007-02-09
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of retinitis pigmentosa

Exclusion Criteria:

* Cataract
* Extremely low ERG wave amplitude (less than 8% of normal)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Semmelweis University, Dept. of Ophthalmology
Study officials:
affiliation: Semmelweis University, Dept. of Ophthalmology
name: Zoltán Z. Nagy, M.D.
role: STUDY_DIRECTOR
References: